Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
OncoSil Medical Ltd ( (AU:OSL) ) has shared an update.
OncoSil Medical Ltd recently addressed a query from the ASX regarding the disclosure of results from the PANCOSIL trial, a Phase 1-2 feasibility study conducted by Amsterdam University Medical Centre. The trial, which investigates the safety and feasibility of CT-guided percutaneous placement of the OncoSil™ device, showed promising preliminary results, including a 90% feasibility rate for tumor ablation. The company promptly implemented a trading halt to analyze the results and released an announcement to the ASX, highlighting the potential impact of these findings on their operations and market positioning.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is a company operating in the medical industry, focusing on the development and commercialization of innovative medical devices. Their primary product, OncoSil™, is a radionuclide therapy device used in the treatment of pancreatic cancer, specifically targeting unresectable locally advanced pancreatic cancer.
Average Trading Volume: 37,726
Technical Sentiment Signal: Sell
Current Market Cap: A$31.16M
Find detailed analytics on OSL stock on TipRanks’ Stock Analysis page.